JNJ latest news: Eyes strong growth in MedTech, sets sights on top-line expansion

Traders Union
All News
Financial News
Johnson & johnson drops 0.51% today

Highlights

Johnson & Johnson (JNJ) trades at $192.73, above its MA-20 ($186.94), MA-50 ($180.85), and MA-200 ($162.71), indicating multi-term bullish momentum.
The company forecasts over 5% top-line growth in 2026, driven by Innovative Medicine and MedTech segments, despite Stelara's upcoming loss of exclusivity.
Oscillators show extreme overbought conditions with daily RSI at 90.71, while near-term price is expected to consolidate within a $193.20–$193.46 corridor with over 80% probability of further gains.

Forward guidance boosts sentiment despite looming loss of exclusivity

At its third-quarter 2025 earnings call, Johnson & Johnson highlighted expectations of significant growth in its Innovative Medicine and MedTech segments, targeting top-line expansion above 5% in 2026 even as Stelara faces loss of exclusivity. The company’s optimistic forward guidance may positively influence market sentiment.

Momentum strength faces overbought warnings as divergence emerges

Momentum readings are mixed: MACD shows strong bullishness, while ADX indicates sellers are gaining traction. Oscillators signal overbought territory as daily RSI sits at 90.71 and Stoch RSI also registers extreme overbought values, suggesting caution. Bull Power remains positive, indicating buyers still influence intraday moves, but the Awesome Oscillator confirms the prevailing upward trend. JNJ is down $0.99 or 0.51% from the previous close, with no notable opening gap, and the current price is mid-range for the day. Intraday volatility is moderate, with mild selling pressure after the open. Momentum and oscillator signals diverge, highlighting underlying bullish strength facing short-term exhaustion risks.

High upside probability as consolidation limits short-term downside

For the coming week, the expected price corridor is $193.20–$193.46. The probability of a price increase is very high (more than 80%), while a decline appears very unlikely. The baseline scenario envisions the price consolidating within this range near current levels. A bullish breakout above $193.46 may open further upside. Conversely, a move below the $193.20 support would point to a temporary correction, though major longer-term support lies well below the current range.

Viktoras Karapetjanc, expert at Traders Union, sees Johnson & Johnson’s strong technical positioning above all major moving averages as confirmation of robust bullish momentum, with recent company guidance supporting fundamentally-driven optimism. He believes that the market’s positive sentiment—underpinned by growth in the Innovative Medicine and MedTech segments, despite headwinds like Stelara’s patent expiration—should maintain upward pressure, even as some momentum indicators warn of short-term exhaustion. While Karapetjanc notes the risk of minor corrections, he views the overall setup as constructive for further gains in the coming week. "Given the solid macro and fundamental backdrop, I expect JNJ to consolidate near highs and possibly break out if sentiment stays this strong," he says.

Previously, it was observed that Johnson & Johnson delivered strong quarterly results, with both earnings and revenue surpassing expectations. Last time, we reported that the statistical likelihood of further price gains was very low.

Source of Data: JNJ Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.